GPX4 and neoplasm: In this work, we develop a peptide-ferriporphyrin conjugate with tumour microenvironment specific activation for improved tumor penetration and endocytosis, which enables effective inhibition of GPX4 due to the assembly enhanced binding (AEB) effect, ultimately improving its anticancer activity via ferroptosis (Fig. 1).